Amneal Pharmaceuticals Inc - Class A – Cashflow (NASDAQ:AMRX)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 379 M241.82 M65.1 M345.58 M295.1 M339.99 M 339.99 M Mittelzufluss aus Investitionstätigkeit -317.55 M-194.18 M-174.31 M-69.19 M-63 M-112.26 M -112.26 M Zahlungsströme aus der Finanzierungstätigkeit 131.81 M-138.12 M-106.62 M-212.57 M-211.79 M-31.53 M -31.53 M Freier Cashflow 318.21 M192.39 M-23.11 M279.97 M228.53 M254.41 M 254.41 M

Amneal Pharmaceuticals Inc - Class A

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

AMRX

Financials

Amneal Pharmaceuticals Inc - Class A

Nachrichten

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing

Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term

Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX)

Amneal auf Barclays-Konferenz: Strategischer Wandel und Innovationsfokus als Wachstumstreiber

Amneal at Barclays Conference: Strategic Growth and Innovation

New Strong Buy Stocks for March 9th

Best Value Stocks to Buy for March 9th

Amneal Pharmaceuticals: Truist erhöht Kursziel wegen Margenfokus

Truist raises Amneal Pharmaceuticals stock price target on margin focus

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript